AIRS vs SKIN

For growth investors, AirSculpt Technologies, Inc.

(AIRS) is the stronger pick with -7. 9% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). Analysts rate AirSculpt Technologies, Inc. (AIRS) a "Hold" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AirSculpt Technologies, Inc.

(AIRS) delivered a total return of -75. 0%, compared to -92. 7% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: AIRS returned -75. 0% versus SKIN's -91. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Beauty Health Company (SKIN) is the lower-risk stock at 2.

00β versus AirSculpt Technologies, Inc. 's 3. 37β — meaning AIRS is approximately 69% more volatile than SKIN relative to the S&P 500. On balance sheet safety, AirSculpt Technologies, Inc. (AIRS) carries a lower debt/equity ratio of 132% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AirSculpt Technologies, Inc.

(AIRS) is pulling ahead at -7. 9% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -77. 4% for AirSculpt Technologies, Inc.. Over a 3-year CAGR, AIRS leads at 10. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Beauty Health Company (SKIN) is the more profitable company, earning -3.

2% net margin versus -4. 6% for AirSculpt Technologies, Inc. — meaning it keeps -3. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AIRS leads at -1. 0% versus -6. 9% for SKIN. At the gross margin level — before operating expenses — SKIN leads at 65. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, AIRS (0.

1% yield) pays a dividend. SKIN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AirSculpt Technologies, Inc.

(AIRS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AIRS: -75. 0%, SKIN: -91. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AIRS (Healthcare) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.